Study: Allurion Program Can Resolve Type 2 Diabetes, Hypertension, OSA

Allurion Technologies Inc. is sharing results of a randomized, double-blind study that shows significant reductions in type 2 diabetes, hypertension, and obstructive sleep apnea in four months on the Allurion Program. These results improved with the addition of an oral GLP-1 agonist semaglutide.
 
The study randomized 115 patients to either the Allurion Program with or without oral semaglutide and followed for four months. In patients randomized to the Allurion Program alone, weight loss was 13.7% at four months and resolution of type 2 diabetes, hypertension, and obstructive sleep apnea was observed in 55.5%, 58.8%, and 57.8%, respectively. Weight loss improved to 17.6% in the group treated with the Allurion Program and oral semaglutide and co-morbidity resolution improved to 64.7%, 64.3%, and 72%, respectively.
 
“We have been extremely pleased with the results we are seeing in medically complex patients with the Allurion Program, especially the speed with which co-morbidities resolve,” said Mohit Bhandari, M.D., President of IRCAD India and senior author on the study. “We have seen that oral GLP-1 agonists alone are often insufficient to generate such significant results but using them as a tool to augment the results of the Allurion Program could be a promising treatment approach in the future.”

The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Gastric Balloon is an investigational device in the United States.
 
Allurion has previously published findings indicating that providers are interested in combining the Allurion Program with anti-obesity medications. The findings also indicate the rise of GLP-1 agonists has increased patient enquiries and boosted awareness of weight loss treatments like the Allurion Program.
 
“We believe the results of this study provide further validation of the rapid impact the Allurion Program can have in patients with obesity and other co-morbidities,” Allurion Founder/CEO Dr. Shantanu Gaur said. “By combining the Allurion Program with anti-obesity medications, we may be able to improve outcomes even further and reach an even broader segment of the population.”
 
Allurion is based in Natick, Mass.